Skip to content

REGENERX BIOPHARMACEUTICALS, INC.: 10-Q filed 2015-05-15

What REGENERX BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2015-05-15 (fiscal Q1 2015): 24 published measures, 50 facts as tagged in accession 0001144204-15-031410.

This filing

Form
10-Q (quarterly report)
Filed
2015-05-15
Fiscal period
fiscal Q1 2015
Accession
0001144204-15-031410 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All REGENERX BIOPHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-03-311,131,967USD
At 2014-12-31949,191USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-03-314,534,137USD
At 2014-12-312,660,810USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-03-31-3,402,170USD
At 2014-12-31-1,711,619USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-03-311,062,499USD
At 2014-12-31844,043USD
At 2014-03-311,299,928USD
At 2013-12-316,306USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-01-01 to 2015-03-31-1,718,690USD90
2014-01-01 to 2014-03-31-2,125,094USD90

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-01-01 to 2015-03-3140,000USD90
2014-01-01 to 2014-03-310USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-03-31-101,523,045USD
At 2014-12-31-99,804,355USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-03-3111,962USD
At 2014-12-3112,871USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-01-01 to 2015-03-3128,139USD90
2014-01-01 to 2014-03-3183,567USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-03-31-390,972USD90
2014-01-01 to 2014-03-31-363,557USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-03-311,114,253USD
At 2014-12-31930,568USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-01-01 to 2015-03-3142,629USD90
2014-01-01 to 2014-03-3145,706USD90

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-03-31467,492USD
At 2014-12-31409,619USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-03-31261,145USD
At 2014-12-31232,610USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-01-01 to 2015-03-31430,972USD90
2014-01-01 to 2014-03-31363,557USD90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-01-01 to 2015-03-3136,472USD90
2014-01-01 to 2014-03-3174,700USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-03-31101,316,580shares
At 2014-12-31101,316,580shares

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2015-03-3186,300USD
At 2014-12-31121,727USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2015-03-315,752USD
At 2014-12-315,752USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2015-03-31206,347USD
At 2014-12-31177,009USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2015-03-3151,754USD
At 2014-12-3186,525USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-01-01 to 2015-03-31394,500USD90
2014-01-01 to 2014-03-31288,857USD90

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2015-01-01 to 2015-03-31909USD90
2014-01-01 to 2014-03-31916USD90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-03-3128,535USD90
2014-01-01 to 2014-03-31-27,364USD90

Inspect the source

Entity
REGENERX BIOPHARMACEUTICALS, INC. / CIK 0000707511
Captured
SEC response SHA-256
ffc4eb5988984f6f0271e31d8cf8024b0343b848cad3a73089a36cab28954e4d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000707511.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))